查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1737973

全球白细胞介素-2市场：区域分析与预测（2025-2035年）

Interleukin-2 Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

白细胞介素-2 (IL-2) 是细胞激素，可促进 T 细胞（对免疫反应至关重要的白血球）的增殖和分化。

IL-2 具有巨大的治疗潜力，尤其是在癌症免疫疗法和自体免疫疾病的治疗中。在免疫肿瘤学的进展、免疫调节研究的不断深入以及对细胞激素治疗重要性的重新评估的背景下，基于 IL-2 的治疗方法市场正在蓬勃发展。先前已获 FDA核准的IL-2 疗法，例如阿地白介素（Proleukin），已用于治疗转移性黑色素瘤和肾细胞癌 (RCC)，是癌症免疫治疗领域的重要里程碑。近年来，新的製剂和标靶 IL-2 疗法不断涌现，有望改善各种癌症和自体免疫疾病的治疗效果。

由于细胞激素激素疗法的进步、癌症免疫疗法应用的不断拓展以及对免疫调节疗法的需求不断增长，全球IL-2市场正在稳步增长。 IL-2在癌症治疗中的作用以及在治疗慢性自体免疫疾病方面的潜力，使其成为现代医学研究和药物开发的重点领域。

市场的主要成长要素之一是癌症发生率的上升。由于黑色素瘤、肾细胞癌和固体癌的发生率上升，全球癌症负担持续上升。 IL-2已被证明能够增强针对这些传统化疗难以治疗的癌症的免疫反应。因此，随着癌症发生率的上升，对创新癌症免疫疗法的需求日益增长，尤其是基于IL-2的治疗方法。

此外，对免疫疗法研发的大量投资也推动了 IL-2 市场的强劲成长。製药公司和研究机构正在投入大量资源开发更有效、更安全的 IL-2治疗方法，因为人们越来越认识到免疫肿瘤疗法在治疗难治性癌症方面已显示出疗效。 FDA 和 EMA 等政府和监管机构也积极支持包括 IL-2 疗法在内的免疫疗法的开发和核准，这有助于推动市场扩张。例如，NKTR-214 是一种基于 IL-2 的新型治疗药物，旨在与其他免疫疗法联合使用，作为旨在为癌症患者提供持续治疗效果的新一代治疗方法，它的核准正在加速进一步的市场扩张。

本报告调查了全球白细胞介素-2市场，并总结了主要趋势、影响市场的因素分析、法律制度、临床试验趋势、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

目录

执行摘要

第一章全球白细胞介素-2市场：产业展望

  • 市场趋势
  • 法律规范
  • 临床试验分析
  • 市场动态
    • 影响分析
    • 市场驱动因素
    • 市场挑战
    • 市场机会

2. 全球白细胞介素-2 市场（按地区）

  • 北美洲
  • 欧洲
  • 亚太地区
    • 主要发现
    • 市场动态
    • 市场规模及预测

3. 全球白细胞介素-2 市场：竞争格局与公司概况

  • 关键发展和策略
    • M&A
    • 协同努力
    • 业务扩展和资金筹措
    • 产品发布和核准
    • 其他活动
  • 公司简介
    • Bristol Myers Squibb
    • Sanofi SA
    • Corvus Pharmaceuticals
    • Regeneron Pharmaceuticals
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche AG
    • Cue Biopharma

第四章调查方法

Product Code: BHL2881SA

Global Interleukin-2 Market, Analysis and Forecast: 2025-2035

Interleukin-2 (IL-2) is a cytokine that plays a crucial role in the immune system by promoting the growth and differentiation of T cells, a type of white blood cell that is essential for immune responses. IL-2 has significant therapeutic applications, particularly in cancer immunotherapy and autoimmune diseases. The market for IL-2-based therapies has been evolving, driven by advancements in immuno-oncology, increased research into immune modulation, and the growing recognition of the importance of cytokine-based therapies in treating various conditions. Historically, IL-2 therapies such as Aldesleukin (Proleukin), approved by the FDA, have been used primarily for treating metastatic melanoma and renal cell carcinoma (RCC), marking significant milestones in immunotherapy. However, newer formulations and targeted IL-2 therapies are emerging, offering the potential to improve outcomes in various cancers and autoimmune disorders.

The global IL-2 market is growing steadily, fueled by advancements in cytokine-based treatments, expanding applications in cancer immunotherapy, and the increasing demand for immunomodulatory treatments. IL-2's role in cancer treatment and its potential in managing chronic autoimmune diseases make it a vital area of focus in modern medical research and pharmaceutical development.

One of the key drivers of the market is the rising prevalence of cancer. The global cancer burden continues to rise, with increasing rates of melanoma, renal cell carcinoma, and solid tumors. IL-2 has been shown to improve the immune response in cancers that are traditionally hard to treat with standard chemotherapy. As cancer incidence increases, there is a growing demand for innovative immunotherapies, including IL-2-based treatments.

Moreover, the IL-2 market is experiencing robust growth due to significant investments in immunotherapy research. Pharmaceutical companies and research institutions are pouring resources into the development of more effective and safer IL-2 therapies. This investment is driven by the increasing recognition of the effectiveness of immuno-oncology treatments in treating cancers that were previously difficult to manage. In addition, governments and regulatory bodies, such as the FDA and EMA, are offering more support for the development and approval of immunotherapies, including IL-2 treatments. The approval of new IL-2-based therapies such as NKTR-214 for use in combination with other immunotherapies has further propelled the market, as these therapies aim to provide more durable responses for cancer patients.

Despite the promising potential of IL-2 therapies, their high cost remains a significant barrier to widespread adoption. Aldesleukin (Proleukin), for example, is expensive, and while newer engineered IL-2 treatments may offer better outcomes, they come with high price tags that limit their accessibility, particularly in developing regions or for patients without insurance coverage. Also, high-dose IL-2 therapy is associated with severe side effects, including fever, chills, nausea, hypotension, and organ toxicity. These side effects can deter patients from undergoing treatment and limit the overall efficacy of IL-2-based therapies, especially in the long term. Efforts are ongoing to engineer IL-2 variants that retain efficacy while minimizing toxicities, but the challenge remains a restraint on market growth.

The global Interleukin-2 (IL-2) market is evolving rapidly, with major pharmaceutical companies and emerging biotech firms driving innovation. The market is highly fragmented, with significant ongoing research into expanding IL-2's use in treating cancer and autoimmune disorders such as lupus and multiple sclerosis. Companies are increasingly focusing on improving patients' quality of life by addressing immune-related issues alongside disease treatment, marking a transformative phase for the IL-2 market.

The Interleukin-2 (IL-2) market is undergoing significant transformation, driven by emerging trends in immunotherapy and advancements in biotechnology. One of the key trends is the increasing focus on personalized medicine, where IL-2 treatment plans are being tailored to individual patients' genetic profiles, disease progression, and immune system responses. With a deeper understanding of the molecular mechanisms behind diseases such as cancer and autoimmune disorders, biotech companies are investing in genetic research and biomarkers to identify which patients are most likely to benefit from IL-2-based therapies. This personalized approach has the potential to optimize treatment outcomes, minimize side effects, and improve overall patient well-being.

Another major trend is the growing demand for engineered IL-2 therapies that are more targeted and effective compared to traditional formulations. Engineered IL-2s such as NKTR-214 (bempegaldesleukin) are designed to enhance the selective activation of the immune system, particularly in tumor environments. These therapies have shown promising results in clinical trials, especially when combined with checkpoint inhibitors such as PD-1/PD-L1 inhibitors. IL-2-based combination therapies are gaining traction in oncology, especially for the treatment of solid tumors, where traditional therapies have shown limited success. Additionally, there is increasing interest in non-cancerous applications of IL-2, including its potential for managing autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis.

As healthcare access expands globally, the demand for IL-2 therapies is expected to rise, particularly in emerging markets where immunotherapy treatments are becoming more accessible. Pharmaceutical companies are focusing on improving affordability through patient assistance programs, pricing strategies, and distribution partnerships. These efforts aim to make IL-2-based therapies more widely available, especially in low- and middle-income regions, where the demand for effective treatments for cancer and autoimmune diseases is increasing. Furthermore, the rise of digital health tools and telemedicine platforms is enhancing the management of IL-2 therapies. These tools allow healthcare providers to remotely monitor patient responses, adjust treatment regimens, and ensure better patient adherence, particularly in long-term treatment scenarios.

In conclusion, the Interleukin-2 (IL-2) market is poised for continued growth, driven by innovations in engineered IL-2 therapies, personalized medicine, and increased access to cutting-edge treatments worldwide. While challenges such as the high cost of biologic therapies and side effects persist, ongoing research into more targeted and safer IL-2 therapies offers hope for improved treatment outcomes. With increasing global healthcare access, the market is positioned for expansion, especially as IL-2 therapies are incorporated into combination treatments and new therapeutic areas, such as autoimmune diseases. As innovation continues, both large pharmaceutical companies and emerging biotech firms will fuel competition, ultimately improving the quality of life for patients undergoing IL-2-based treatments.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Interleukin-2 Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Clinical Trial Analysis
  • 1.5 Market Dynamics
    • 1.5.1 Impact Analysis
    • 1.5.2 Market Drivers
    • 1.5.3 Market Challenges
    • 1.5.4 Market Opportunities

2. Global Interleukin-2 Market, by Region, $Million, 2023-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Interleukin-2 Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Interleukin-2 Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
        • 2.2.3.1.5 Spain
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Interleukin-2 Market, by Country
        • 2.3.3.1.1 Japan

3. Global Interleukin-2 Market: Competitive Landscape and Company Profiles

  • 3.1 Key Development and Strategies
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 Bristol Myers Squibb
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Target Customers/End-Users
      • 3.2.1.4 Key Personnel
      • 3.2.1.5 Analyst View
    • 3.2.2 Sanofi S.A.
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Target Customers/End-Users
      • 3.2.2.4 Key Personnel
      • 3.2.2.5 Analyst View
    • 3.2.3 Corvus Pharmaceuticals
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Target Customers/End-Users
      • 3.2.3.4 Key Personnel
      • 3.2.3.5 Analyst View
    • 3.2.4 Regeneron Pharmaceuticals
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Target Customers/End-Users
      • 3.2.4.4 Key Personnel
      • 3.2.4.5 Analyst View
    • 3.2.5 Merck & Co., Inc.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Target Customers/End-Users
      • 3.2.5.4 Key Personnel
      • 3.2.5.5 Analyst View
    • 3.2.6 F. Hoffmann-La Roche AG
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Target Customers/End-Users
      • 3.2.6.4 Key Personnel
      • 3.2.6.5 Analyst View
    • 3.2.7 Cue Biopharma
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Target Customers/End-Users
      • 3.2.7.4 Key Personnel
      • 3.2.7.5 Analyst View

4. Research Methodology

List of Figures

  • Figure: Global Interleukin-2 Market (by Region), $Million, 2024 and 2035
  • Figure: Global Interleukin-2 Market Key Trends, Impact Analysis,

List of Tables

  • Table: Global Interleukin-2 Market Dynamics, Impact Analysis
  • Table: Global Interleukin-2 Market (by Region), $Million, 2023-2035